1,271 Shares in BioNTech SE (NASDAQ:BNTX) Bought by Rakuten Securities Inc.

Rakuten Securities Inc. acquired a new position in shares of BioNTech SE (NASDAQ:BNTX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 1,271 shares of the company’s stock, valued at approximately $134,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BNTX. US Bancorp DE grew its position in BioNTech by 8.2% during the 1st quarter. US Bancorp DE now owns 4,386 shares of the company’s stock worth $749,000 after acquiring an additional 332 shares during the last quarter. BlackRock Inc. grew its position in BioNTech by 25.9% during the 1st quarter. BlackRock Inc. now owns 1,610,975 shares of the company’s stock worth $274,768,000 after acquiring an additional 331,101 shares during the last quarter. Great West Life Assurance Co. Can grew its position in BioNTech by 522.3% during the 1st quarter. Great West Life Assurance Co. Can now owns 2,041 shares of the company’s stock worth $371,000 after acquiring an additional 1,713 shares during the last quarter. Cibc World Market Inc. grew its position in shares of BioNTech by 6.4% in the 1st quarter. Cibc World Market Inc. now owns 2,983 shares of the company’s stock valued at $509,000 after buying an additional 180 shares during the last quarter. Finally, Sei Investments Co. grew its position in shares of BioNTech by 58.1% in the 1st quarter. Sei Investments Co. now owns 145,886 shares of the company’s stock valued at $24,882,000 after buying an additional 53,595 shares during the last quarter. Institutional investors own 15.52% of the company’s stock.

BioNTech Stock Up 0.1 %

Shares of NASDAQ:BNTX opened at $86.40 on Thursday. The company has a market capitalization of $20.54 billion, a price-to-earnings ratio of 20.97 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The business’s 50-day moving average is $91.49 and its 200-day moving average is $97.57. BioNTech SE has a 1 year low of $85.21 and a 1 year high of $125.83.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. Equities research analysts predict that BioNTech SE will post -1.67 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Oppenheimer assumed coverage on BioNTech in a research report on Friday, January 5th. They issued a “market perform” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $107.00 price target on shares of BioNTech in a research report on Wednesday. JPMorgan Chase & Co. reduced their price target on BioNTech from $99.00 to $90.00 and set an “underweight” rating on the stock in a research report on Friday, March 22nd. The Goldman Sachs Group reduced their price target on BioNTech from $113.00 to $100.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 28th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 price target on shares of BioNTech in a research report on Thursday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, BioNTech presently has an average rating of “Hold” and an average price target of $120.40.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.